SYNTHESIS & CHARACTERIZATION OF NEW MACROMOLECULAR CONTRAST AGENTS

合成

• 批准号: 7601814
• 负责人: Robert Charles Brasch
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-30 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7601814
• 关键词: Blood; Categories; Characteristics; Chemical Structure; Class; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Data; Diagnostic; Funding; Grant; Image; Institution; Mass Spectrum Analysis; Measurement; Medical Imaging; Methods; Microvascular Permeability; Molecular; Molecular Weight; Organ; Pharmacologic Substance; Procedures; Property; Research; Research Personnel; Resources; Role; Source; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Structure; Tissues; United States National Institutes of Health; chemical synthesis; size; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Introduction: Imaging contrast agents (or contrast media) are a category of diagnostic pharmaceuticals for enhancing the image contrast of organs/tissues and for displaying the organ function in medical imaging. Macromolecular contrast agents have found their important role in the characterization of microvascular permeability of tumor vessels, due to their blood-pool characteristics. New dendritic contrast agents with well-defined structure, high degree of size homogeneity, varying molecular weights and polyethyleneglycol (PEG) cores, will be synthesized. Their average molecular weights (MW) and MW distribution will be obtained from mass spectrometry, which info will be highly helpful for the chemical synthesis and for the study of their structure-property relationship. In addition, some new small molecular intermediates, which are attributed to the image contrast, need the structure characterization by mass spectrometry, too. Methods: For different macromolecular derivatives (MW 3,000 - 150,000), MALDI-MS could be used for the measurements of their MW and distributions in MW. For small molecular compounds (MW 500 - 2000), ESI-MS or other approaches may be applicable. Results & Discussion: Mass spectra data will be correlated with the data from physical and imaging measurements, the relationship between chemical structure and physical (or imaging) properties will be sought for this new class of macromolecular contrast agents. During the synthesis, the mass spectra data will be highly helpful in the guidance and optimization of synthetic procedures.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 前言：成像造影剂(或造影剂)是医学成像中用于提高器官/组织图像对比度和显示器官功能的一类诊断药物。由于大分子造影剂的血池特性，它们在表征肿瘤血管的微血管通透性方面发挥了重要作用。新型树枝状造影剂具有良好的结构、高度的尺寸均匀度、可变的相对分子质量和聚乙二醇核，将被合成。它们的平均相对分子质量(MW)和相对分子质量分布将通过质谱学获得，这些信息将对化学合成和研究它们的结构-性质关系有很大的帮助。此外，一些新的小分子中间体，由于图像对比度的原因，也需要用质谱仪进行结构表征。 方法：用MALDI-MS测定不同大分子衍生物的相对分子质量及其在相对分子质量中的分布。对于小分子化合物(相对分子质量为500-2000)，可采用电喷雾质谱(ESI-MS)或其他方法。 结果与讨论：质谱学数据将与物理和成像测量数据相关联，这类新的大分子造影剂将寻求化学结构与物理(或成像)性质之间的关系。在合成过程中，质谱学数据将对合成过程的指导和优化有很大的帮助。